- Home
- REXR vs MIRM Comparison
REXR vs MIRM Comparison
Compare REXR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REXR | MIRM |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.2B |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | REXR | MIRM |
|---|---|---|
| Price | $37.01 | $97.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $41.00 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 2.1M | 649.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,133,000.00 | $19,138,000.00 |
| Revenue This Year | $0.09 | $26.22 |
| Revenue Next Year | $2.99 | $22.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.13 | N/A |
| 52 Week Low | $32.14 | $63.23 |
| 52 Week High | $44.38 | $130.00 |
Technical Indicators
Market Signals| Indicator | REXR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 40.55 |
| Support Level | $34.75 | $88.08 |
| Resistance Level | $37.87 | $98.03 |
| Average True Range (ATR) | 0.60 | 3.30 |
| MACD | -0.02 | 0.33 |
| Stochastic Oscillator | 57.78 | 24.02 |
Price Performance
Historical ComparisonAbout REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust focused on owning, operating and acquiring industrial properties in Southern California infill markets. Its goal is to generate attractive risk-adjusted returns for the stockholders by providing superior access to industrial property investments and mortgage debt investments secured by industrial property in high-barrier Southern California infill markets. The company generates revenue from rental income derived from properties in its portfolio.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.